Compare Stocks

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Inventronics Limited designs, manufactures, and sells protective enclosures and related products for the telecommunications, cable, electric transmission, oil and gas, and other industries in North America. The company offers CP Pedestal series for CATV distribution equipment; IVT BOBCAT co-locate cabinet series for broadband node locations supporting remote deployment of network electronics, including power supply, batteries, and RF components; SG pedestals for utility and communication industries; and MDU enclosure series for cable and telecom companies. It also provides Nema 4/4x enclosures for wall-mount, pole-mount, and free-standing enclosures with one door; Nema 4/4x cabinets for control gateways or data rooms; and Nema 1/12 cabinets and enclosures for use in data and electronic control applications. In addition, it offers M/U pedestal series for power/cable TV/telecom subsurface-to-ground access; residential, commercial, and industrial enclosures for new and existing developments; urban and rural locations; termination, splicing, and loading of buried wire and cable; and secondary junction boxes/pedestals. Further, the company provides FDE enclosures designed for fiber optic splicing, as well as organization, splicing, and security for FTTx, broadband, distribution, and building entrance applications; traffic control enclosures for traffic control equipment; and urban refuse and recycling bins, such as single refuse and recycle bins, single dog bag dispensers, refuse/dog dispenser combos, refuse/recycling bin combos, and refuse/recycling/dog dispenser combos. Inventronics Limited was founded in 1970 and is based in Brandon, Canada.

Meredith Corp. engages in television broadcasting and magazine advertising business. It operates through the Local Media and National Media business segments. The Local Media segment includes television stations and offers websites, mobile-optimized websites, and mobile applications. The National Media segment consists of national consumer media brands delivered via multiple media platforms including print magazines and digital and mobile media, brand licensing activities, database-related activities, and business-to-business marketing products and services. The company was founded by Edwin Thomas Meredith in 1902 and is headquartered in Des Moines, IA.

Savaria Corporation provides accessibility solutions for the elderly and physically challenged people in Canada, the United States, Europe, and internationally. The company operates in two segments, Accessibility and Patient Care. The Accessibility segment designs, manufactures, distributes, and installs a portfolio of accessibility products, including commercial and home elevators, stairlifts, platform lifts, and wheelchair lowered-floor accessible conversions for selected brands of minivans, personal, residential, or commercial applications. The Patient Care segment designs, manufactures, distributes, and installs ceiling lifts, patient transfer slings and accessories, floor lifts, standing aids, bathing equipment, medical beds, therapeutic support surfaces, and pressure management products used in healthcare facilities and home care settings. It sells its products through dealers or direct stores to end-user customers. The company was founded in 1979 and is headquartered in Laval, Canada.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.